ANXA5 and breast cancer: An Annexin V and PI assay revealed significantly more healthy cells in the TP53β N340D breast cancer group (−46.2 ± 9.57) compared to TP53β WT controls (−58.8 ± 2.57) following DXR treatment (p = 0.0421) (Fig. 2G-H).